Impact News +++ Kinnevik names Helena Saxon as new CEO (SeekingAlpha) +++ KINNEVIK B Aktie +3,51%

ELEDON Aktie

>ELEDON Aktienkurs

3.38 EUR (TradegateBSX)

Ask: 3.44 EUR / 734 Stück

Bid: 3.32 EUR / 764 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ELEDON Aktie über LYNX handeln

Intraday

1 Jahr

>ELEDON Performance

1 Woche: -1,8%

1 Monat: -1,8%

3 Monate: +75,0%

6 Monate: +168,8%

1 Jahr: +24,4%

laufendes Jahr: +154,5%

>ELEDON Aktie

Name:

ELEDON PHARMACEUT.DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US28617K1016 / A2QL00

Symbol/ Ticker:

2TK (Frankfurt) / ELDN (NASDAQ)

Kürzel:

FRA:2TK, ETR:2TK, 2TK:GR, NASDAQ:ELDN

Index:

Webseite:

https://eledon.com/

Profil:

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for transplantation, autoimmune diseases, and neurodegenerative conditions. The company's lead investigational product is tegoprubart, ..
>Volltext..

Marktkapitalisierung:

258.79 Mio. EUR

Unternehmenswert:

211.27 Mio. EUR

Umsatz:

EBITDA:

-74.52 Mio. EUR

Nettogewinn:

-67.35 Mio. EUR

Gewinn je Aktie:

-0.74 EUR

Schulden:

0.48 Mio. EUR

Liquide Mittel:

5.3 Mio. EUR

Operativer Cashflow:

Bargeldquote:

8.25

Umsatzwachstum:

Gewinnwachstum:

-75.94%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ELEDON

Letzte Datenerhebung:

25.05.26

>ELEDON Kennzahlen

Aktien/ Unternehmen:

Aktien: 77.19 Mio. St.

Frei handelbar: 95.48%

Leerverk. Aktien: 9.79%

Rückkaufquote: -17.88%

Mitarbeiter: 33

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 122.37%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 6.19

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -50.75%

Eigenkaprendite: -72.68%

>ELEDON Peer Group

Gesundheit, Antikörper- Behandlung, Nierenerkrankungen & -behandlung, Neurologie/ psychische Behandlung/ Schlaganfälle, Stoffwechselerkrankungen (Diabetes/ Adipositas)
>Alle Branchen..

>ELEDON Chart & Kurs - NASDAQ

>ELEDON News

20.05.26 - 22:09	Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress (GlobeNewswire EN)
	Eledon to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at ATC...

13.05.26 - 22:09	Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire EN)
	Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights...

30.04.26 - 14:18	NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 (GlobeNewswire EN)
	NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones...

20.04.26 - 13:42

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference (GlobeNewswire EN)

ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company's strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company's development strategy....

19.03.26 - 22:24	Eledon Pharmaceuticals GAAP EPS of -$0.52 beats by $0.15 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.03.26 - 22:12	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results (GlobeNewswire EN)
	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results...

16.03.26 - 21:54	Eledon sees promising data for tegoprubart in islet transplant type 1 diabetes. (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

16.03.26 - 12:03	Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine (GlobeNewswire EN)
	Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine...

11.03.26 - 22:24	Eledon Pharmaceuticals: Strategische Einblicke in Transplantations-Therapien auf der Leerink-Konferenz (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

10.03.26 - 13:21	Eledon Pharma rises on FDA orphan status for lead asset (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.03.26 - 12:03	Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation (GlobeNewswire EN)
	Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation...

10.03.26 - 11:48	NewcelX and Eledon partner for NCEL-101 programme (PBR)
	The collaboration will integrate NewcelX's NCEL-101 with Eledon's investigational anti-cluster of differentiation 40 ligand (anti-CD40L) monoclonal antibody, tegoprubart (AT-1501), to support durable, immune-protected islet replacement and develop a The post NewcelX and Eledon partner for NCEL-101 programme appeared first on Pharmaceutical Business review....

09.03.26 - 12:02	NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes (PR Newswire)
	Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq: NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Diabetes, today announced a collaborative......

04.03.26 - 22:09	Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire EN)
	Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference...

12.02.26 - 17:24	Eledon Pharmaceuticals auf dem Guggenheim Summit: Vielversprechender Weg für Tegoprubart trotz Rückschlägen in Studien/n (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

05.02.26 - 22:12	Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire EN)
	Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026...

23.01.26 - 13:03	Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium (GlobeNewswire EN)
	Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at ASTS...

08.01.26 - 22:09	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook (GlobeNewswire EN)
	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook...

01.12.25 - 13:03	Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference (GlobeNewswire EN)
	Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference...

18.11.25 - 23:48	Eledon Pharmaceuticals: Aktie legt nach positiven Daten zu Inselzelltransplantation zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Zeit bringt auch dem Ungeduldigsten das Warten bei. - Elfriede Hablé

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram